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Effectiveness of fecal-derived microbiota
transfer using orally administered capsules
for recurrent Clostridium difficile infection
Bruce E Hirsch1*†, Nimit Saraiya1, Kaitlin Poeth1, Rebecca M Schwartz2, Marcia E Epstein1 and Gerard Honig3†
Abstract
Background: Clostridium difficile infection (CDI), a complication of antibiotic-induced injury to the gut microbiome, is
a prevalent and dangerous cause of infectious diarrhea. Antimicrobial therapy for CDI is typically effective for acute
symptoms, but up to one third of patients later experience recurrent CDI. Fecal-derived microbiota transplantation
(FMT) can ameliorate the underlying dysbiosis and is highly effective for recurrent CDI. Traditional methods of FMT
are limited by patient discomfort, risk and inefficient procedures. Many individuals with recurrent CDI have extensive
comorbidities and advanced age. Widespread use of FMT requires strategies that are non-invasive, scalable and
applicable across healthcare settings.
Methods: A method to facilitate microbiota transfer was developed. Fecal samples were collected and screened for
potential pathogens. Bacteria were purified, concentrated, cryopreserved and formulated into multi-layered capsules.
Capsules were administered to patients with recurrent CDI, who were then monitored for 90 days.
Results: Thirteen women and six men with recurrent CDI were provided with microbiota transfer with orally
administered capsules. The procedure was well tolerated. Thirteen individuals responded to a single course. Four
patients were cured after a second course. There were 2 failures. The cumulative clinical cure rate of 89% is similar
to the rates achieved with reported fecal-derived transplantation procedures.
Conclusions: Recurrent CDI represents a profound dysbiosis and a debilitating chronic disease. Stable cure can be
achieved by restoring the gut microbiome with an effective, well-tolerated oral capsule treatment. This strategy of
microbiota transfer can be widely applied and is particularly appropriate for frail patients.
Keywords: Clostridium difficile, Fecal transplantation, Fecal microbiota transfer, Capsule, Diarrhea, Microbiota,
Microbiome, Fecal microbiota transplantation
Background
Clostridium difficile infection (CDI) has been identified
by the Centers for Disease Control and Prevention as
one of the most prevalent hospital-acquired infections in
the United States [1] and an “immediate public health
threat that requires urgent and aggressive action” [2].
There are an estimated 453,000 cases of CDI per year in
the US, with 29,000 associated deaths [3,4]. CDI leads to
multiple morbidities [2,5] and billions of dollars in ex-
cess medical costs [6-8]. The only widely available treat-
ments for recurrent CDI are antimicrobials directed
against the pathogen. While this is generally effective for
acute symptoms, up to one third of patients experience
recurrent infection, and with each failure of antibiotic
treatment, chances of later successful treatment diminish
[3,7,9-13]. Recurrent CDI has been defined as the recur-
rence or continuation of diarrhea symptoms, with a
positive diagnostic test for Clostridium difficile in the
stool, after the completion of therapy for initial CDI epi-
sode [14]. Patients with CDI, especially the recurrent
form, experience severe morbidity, impaired functioning
and risk of clinical decompensation, and pose prolonged
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infectious risk to others. Hypervirulent strains of Clos-
tridium difficile have emerged since 2000 and are associ-
ated with particularly high risk of recurrent CDI [15].
CDI is a disorder of the gastrointestinal (GI) micro-
biota. The human-associated microbiota is a dense and
diverse population of symbiotic bacteria which use the
human body (particularly the colon) as habitat [16]. The
microbiota has co-evolved with humans and plays essen-
tial roles in health and disease. One of its most crucial
roles is colonization resistance, or the prevention of
overgrowth by pathogenic bacteria via direct competition
and additional mechanisms [17-19]. When the microbiota
is injured, most often following oral antibiotic administra-
tion, colonization resistance is impaired, allowing patho-
gens such as Clostridium difficile to proliferate and
dominate the gut ecosystem [17]. Antibiotics targeted
against CDI may eradicate the active infection, but do
not redress (andmay even exacerbate) long-lasting dysbiosis
of themicrobiota, themajor risk factor for relapse [20].
The role of the microbiota in antibiotic-induced diar-
rhea was recognized long before the identification of
specific pathogens responsible for this condition. This
understanding has stimulated significant interest in
fecal-derived microbiota transfer (FMT): the transplant-
ation of fecal-derived bacteria from a healthy individual
into the GI tract of the affected patient [21-25]. This
strategy, which utilizes the complex fecal microbiota of a
healthy donor to reconstitute the normal microbiota, is
an effective and appropriate treatment for recurrent CDI
or pseudomembranous colitis, as supported by many
case series reports [11,22,25-51] and a randomized trial
[52]. FMT can be administered by various modalities in-
cluding instillation of donor fecal content by colono-
scopic or nasogastric intubation [28]. In the present
work, we describe the use of orally administered cap-
sules to deliver cryopreserved fecal-derived bacteria for
the treatment of recurrent CDI.
Methods
Inclusion criteria
FMT by capsule for the treatment of recurrent CDI is
offered as a standard treatment by the North Shore LIJ
Division of Infectious Diseases. The present work repre-
sents a retrospective chart review of all such cases en-
countered between April 2013 and February 2014. These
dates were determined by the North Shore LIJ Institu-
tional Review Board, and did not represent start or stop
of a clinical trial. Eligible candidates for the procedure
are individuals with two or more prolonged, severe and/
or recurrent episodes of CDI after therapy with metro-
nidazole, vancomycin, and/or fidaxomicin. Subjects were
adults over 18 years of age who were receiving antibiotic
treatment for CDI at the time of evaluation and were cap-
able of swallowing capsules. Exclusion criteria included
gastroparesis, neutropenia, ileus, and hemodynamic
instability.
Ethics & compliance
All work was evaluated and approved by the Institu-
tional Review Board of the North Shore-Long Island
Jewish Health System. All procedures were performed
under and compliant with the current policy of the Food
and Drug Administration on the use of FMT for recur-
rent CDI [53]. An Investigational New Drug application
was submitted to the Food and Drug Administration
prior to the issuance of the current guidance, but later
withdrawn at the FDA’s recommendation.
Fecal matter donation
Donors were three healthy volunteers unrelated to the
recipients. Individuals in good health who had not re-
ceived antibiotics for at least 6 months prior to the pro-
cedure were considered as candidates for stool donation.
Individuals with a history of irritable bowel disease, in-
flammatory bowel disease, body mass index over 25,
diabetes mellitus or psychiatric illness were excluded.
Extensive screening for potential pathogens in the blood
and feces was performed using standard clinical diagnos-
tic protocols at the North Shore-LIJ Core Laboratory.
Testing was done on-site except where noted. Following
a standard small-volume venous blood draw, the follow-
ing serologic tests were performed by chemiluminescent
microparticle immunoassay: combined HIV-1 and HIV-2
Ab/Ag; Hepatitis A (total anti-hepatitis A virus IgG/
IgM); Hepatitis B (HbsAg and anti-Hbs); and Hepatitis
C (anti-Hepatitis C Virus). Treponema pallidum particle
agglutination test was performed for syphilis. Enzyme
immunoassay for Human T-Lymphotrophic Viruses
types I and II was performed at Mayo Medical Labora-
tories (Rochester, NY). At the time of stool donation, the
sample was evaluated as follows. PCR for the toxin B
gene of Clostridium difficile was performed using the
BD GeneOhm Cdiff Assay according to the manufac-
turer’s instructions. Stool was plated by a clinical micro-
biologist using the following media: 5% sheep blood
agar; MacConkey agar; MacConkey agar with sorbitol;
and Hektoen enteric agar plates were incubated aerobic-
ally at 35°C. CIN Yersina selective agar plates were incu-
bated at room temperature. Campylobacter agar plates
were incubated at 42°C anaerobically using the gas-pack
method. Plates were examined by an experienced obser-
ver for Salmonella, Shigella, Campylobacter, E. coli
O157, Yersinia, Vibrio, Aeromonas and Plesiomonas col-
onies. For ova and parasite testing, an additional stool
sample was collected into fixative and evaluated by mi-
croscopy. A donor sample was used for FMT if and only
if a complete set of negative screening results had been
received for the donor, not more than 30 days prior to
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the date of sample collection. No instances of disqualify-
ing test results were obtained from such screening. Be-
tween screening and donation, donors were instructed
to abstain from antibiotics; bismuth preparations; under-
cooked meat, poultry, seafood or eggs; travel outside of
the United States; and any known infectious contacts.
Donors were queried for any intercurrent illness at the
time of donation. For fecal sample collection, donors
were received in an outpatient clinic by a healthcare pro-
vider who performed screening and provided guidance
regarding sample collection. Sample collection was per-
formed by the donor at the clinic using sterile transfer
materials and appropriate personal protective equip-
ment. The sample was then remitted to the healthcare
provider, who then submitted it to a laboratory techni-
cian for processing.
Capsule formulation
Processing was performed with strict environmental
control not later than 6 hours following defecation. All
vessels used for sample handling were sterile, sealed
single-use plastic (Nalgene), with the exception of a
homogenizer (Black & Decker) which was disinfected
and washed with 10% bleach, detergent and water prior
to use. All reagents were sterile USP grade. Wet weight
of stool was recorded; stool was then homogenized
briefly in 350 mL 0.9% NaCl in water and aliquoted into
sterile disposable conical centrifuge tubes. Samples were
then centrifuged at 200 g for 10 minutes. Upon removal
from centrifuge, a pellet of insoluble material formed.
Supernatant was then decanted into new centrifuge
tubes and centrifuged at 4600 g for 15 minutes. Two
layers of pellet typically formed: a lower pellet of insol-
uble material of variable size, and a larger, dense bacter-
ial pellet. The supernatant was removed and the upper
pellets were re-suspended in 0.9% sodium chloride with
a final concentration of 15% glycerol (v/v). Concentra-
tion was calculated as the wet weight of input material
over the final slurry volume; typical concentration for
preparations used was 0.5 g/mL. The resulting FMT
slurry was used to fill 5 mL or 10 mL syringes and im-
mediately frozen over dry ice and stored at −80°C. Dur-
ation of storage at −80°C was 1–3 weeks. Prior to use,
syringes were transferred to −20°C storage and used
within 6 weeks. Immediately prior to FMT, aliquots were
thawed. Aliquots of 0.4 mL of FMT slurry were dis-
pensed into Size 1 acid-resistant hypromellose capsules
(DRCaps, manufactured by Professional Compounding
Centers of America, Houston, TX), subsequently placed
within Size 0 acid-resistant hypromellose capsules and
then nested within Size 00 gelatin Caps (Capsuline,
Pompano Beach, FL). Capsules were administered imme-
diately upon filling and capping.
FMT procedure
Informed consent was obtained from each patient. Anti-
microbial treatment for CDI was discontinued the day
prior to FMT. A proton pump inhibitor was given on
the evening and the morning prior to the procedure.
Patients were instructed to eat lightly on the morning of
the procedure. Under direct supervision in an out-
patient office setting, the patients ingested 6–22 capsules
(average of 10 ± 3 standard deviation) and were moni-
tored for and immediate adverse effects. Each patient
was offered 8–12 capsules. One patient (see Subject S,
Additional file 1: Table S2) developed anxiety and de-
clined additional capsules after ingesting only 6. This
patient’s initial course was the only instance in which
the number of capsules was limited due to the patient’s
request. This same individual failed treatment despite
later being provided with an augmented dose of 22 cap-
sules at his family member’s request. He had no diffi-
culty ingesting the capsules on subsequent courses.
Patients were instructed to not eat and to remain up-
right for 1 hour after ingesting capsules. The procedures
were performed between April 2013 and February 2014.
Estimation of dose
The mean mass of initial fecal matter used to produce a
successful FMT dose was 2.3 g. Although we did not
quantitatively assess the density and viability of bacteria
delivered, we can estimate the bacterial load transferred
based on results from a flow cytometry study of bacterial
population in fecal matter from healthy individuals [54].
According to that work, feces contains, on average,
8.6×1010 bacterial cells per gram of wet weight; vital
staining indicated that 49% had an intact cell membrane
(conservative marker of viability) for an estimated
4.2×1010 intact bacteria per gram input material. Thus
we estimate that a typical FMT dose contained 9.7×1010
viable bacteria at the time of initial production. An esti-
mate of the input material corresponding to each treat-
ment instance is provided in a table (see Additional file
1: Table S2).
Adjunctive procedures
Patients were encouraged to consume 4 ounces of Kefir
fermented milk product twice daily and were given a list
of “pre-biotic” nutrients to consume for at least 3 days
after FMT. In the circumstance of persistent or recur-
ring CDI, patients were instructed to immediately re-
sume CDI antimicrobial therapy and report their clinical
status.
Outcomes
Patients were followed by phone interview within 2 days,
within 3 weeks and after 90 days to assess their response
to the procedure. They were instructed to promptly
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report clinical changes and were specifically evaluated
for the recurrence of symptoms associated with their
previous episodes of CDI-associated diarrhea. Diarrhea
was defined as ≥ 3 unformed stools within 24 hours.
They were simultaneously assessed for adverse effects.
Patients with recurrent CDI were re-treated with anti-
microbial therapy and subsequently offered repeat FMT.
When performed, sequential FMT treatments were ad-
ministered approximately six weeks after the previous
FMT. After each instance of FMT, follow-up was ex-
tended for an additional 90 days. The primary end point
was resolution of CDI associated diarrhea without re-
lapse after 90 days. Recurrence was defined as diarrhea
with positive stool testing for Clostridium difficile toxin
B by PCR. Diarrhea explained by other causes, respond-
ing to etiology-specific therapy, with negative stool tests
for Clostridium difficile toxin B, were not considered as
FMT failures. Cases were tabulated and mean values and
proportions were calculated.
Results
A total of 19 patients with recurrent CDI were identified
as candidates for FMT. Patient demographics, medical
history and FMT treatment details are indicated (see
Additional file 1: Table S2). Patient ages ranged from
26–92 years, with a mean of 61 years. There were 13 fe-
males and 6 males. The patients had an average of 4
CDI recurrences (range, 2–8). Co-morbid conditions
were common (average of 2.5 per patient) and are indi-
cated in Table 1. Only one patient had no other chronic
condition. FMT was administered in the outpatient set-
ting in all instances.
The primary endpoint was lasting resolution of CDI
diarrhea, assessed 90 days after the last FMT. Thirteen
patients (68%) had resolution after a single instance of
FMT treatment. Of 6 patients that did not respond to
the initial treatment, 4 went on to have resolution after
one subsequent FMT treatment, for a cumulative cure
rate of 89%. Repeat FMT procedures were performed
approximately six weeks after the initial FMT. There
was only one patient (Subject S, Additional file 1: Table
S2) who had more than 2 treatments; he received 4
treatments without long term resolution of diarrhea. In
successful courses, clinical improvement was noted
within three days of FMT; in most cases, symptoms
gradually improved over the course of two weeks. The
FMT procedure was well tolerated. There was no dis-
taste, respiratory distress nor immediate discomfort with
ingestion of capsules. There were no infectious compli-
cations. Abdominal pain was reported post-procedure by
five subjects. The pain was mild and transient in four
cases. There was one instance of moderate to severe
epigastric distress which required narcotic analgesics.
The corresponding patient (Subject G, Additional file 1:
Table S2) was a 44-year old woman with chronic abdom-
inal pain and irritable bowel syndrome (IBS) in addition
to recurrent CDI. She was hospitalized five days after
FMT. Abdominal CT scan was negative, repeat testing
for Clostridium difficile toxin B by PCR was negative
and pain improved after 3 days. The clinical presentation
was inconsistent with viral gastroenteritis. The pain was
similar to her previous pain episodes. Patients with IBS
did not have improvement in IBS symptoms after FMT.
There were two FMT failures. A 76-year-old man
(Subject O, Additional file 1: Table S2), with 3 CDI re-
currences, diabetes mellitus, hypertension, coronary ar-
tery disease and renal cell carcinoma, experienced soft
stools 11 days after FMT and was provided a course of
oral vancomycin by his primary care physician. He
remained free of CDI after an additional 90 days. The
Table 1 Comorbidities in the study population
Comorbidities Number of patients (of 19)
Cardiovascular 14
Atrial fibrillation 3
Hypertension 8
Cardiomyopathy 1
Coronary artery disease 2
Endocrine 8
Diabetes 2
Polycystic ovary syndrome 1
Hypothyroidism 2
Thyroid nodule 1
Obesity 2
Gastrointestinal 6
Chronic pancreatitis 2
Irritable bowel syndrome 3
Diverticulitis 1
Hematological malignancy 2
Lymphoma 1
Acute myeloid leukemia 1
Solid Malignancies (Renal carcinoma) 1
Immunological (psoriasis) 1
Neurological 8
Dementia 3
Parkinson’s 1
Stroke 1
Chronic pain 3
Psychiatric 3
Anxiety 1
Depression 2
Pulmonary (asthma) 2
Chronic renal insufficiency 1
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second case (Subject S, Additional file 1: Table S2) was
an 84 year old man with dementia, coronary artery dis-
ease, congestive heart failure, arthritis and non-Hodgkins’
lymphoma who had recurrent symptoms consistent with
CDI within 2–4 weeks of each of 4 FMT attempts. He re-
quired hospitalization for diarrhea, dehydration and acute
kidney injury. The diarrhea resolved with oral vanco-
mycin and rifaximin. He developed health-care acquired
pneumonia which was treated with systemic antimicrobial
therapy and oral vancomycin was continued. He did not
develop recurrent diarrhea. He expired from respiratory
failure. His death was considered unrelated to the FMT
procedure.
Discussion
Conventional treatment options for CDI have significant
limitations and are mostly ineffective for the recurrent
form of the infection. Metronidazole and oral vanco-
mycin are standard therapies. Fidaxomicin has been the
only additional pharmaceutical to be approved by the
Food and Drug Administration for CDI over the past
25 years; although its use is associated with lower rates
of recurrence [6], concerns regarding its cost-effectiveness
have limited its adoption [6,55-57]. Although most patients
with CDI experience acute relief with antibiotic therapy,
diarrhea recurs in up to 35% of patients after an initial epi-
sode [58] and up to 60% of patients after a third episode
[11]. Additional strategies include oral vancomycin with an
extended taper; rifaximin; intravenous tigecycline; toxin
binding resins, monoclonal antibodies and various FMT
modalities [29,42,45,59].
The gut lumen comprises an exceptionally dense and
complex microbial ecosystem [60,61].The gut micro-
biome participates in diverse aspects of human biology
including nutrient absorption, gastrointestinal function,
colonization resistance against potential pathogens and
immunomodulation [62]. Vulnerability to CDI is related
to the microbial composition of the gut. Comparative
metagenomic analysis has demonstrated alterations in
microbiota at the phylum level. In one study, when
compared with controls, patients with Clostridium diffi-
cile-associated disease had increases in Firmicutes, Proteo-
bacteria and Actinobacteria with decreases in Bacteroidetes
and in overall diversity of the gut microbiome [63]. Anti-
biotic exposure is the most common risk factor for CDI.
Other risk factors include proton pump inhibitors, ad-
vanced age, gastrointestinal surgery and serious underlying
illness or comorbidities [64]. Antibiotic administration is
associated with long term changes in gut microbiota. For
example, significant alterations in gut microbiome were
found to persist two years after a 7-day course of clinda-
mycin [65].
FMT has been shown to be effective using multiple
methods of administration. Introduction of fecal-derived
bacteria into the gut can be accomplished in numerous
ways [37,66]. Successful FMT is associated with marked
change of gut microbiota with enhanced diversity and
increase in relative abundance of members of the genus
Bacteroides [67]. An early case report described dra-
matic clinical improvement of acute severe CDI associ-
ated with FMT performed by enema [68]. A high
success rate for recurrent CDI was documented with
donor stool administration via nasogastric tube [69].
Multiple reports document excellent results with colo-
noscopic instillation of fecal-derived bacteria into ter-
minal ileum and cecum [70-72]. A recently published
randomized clinical trial evaluated nasoduodenal infu-
sion of donor feces versus oral vancomycin; this trial
was terminated prematurely as the remarkably high
rate of success of FMT raised ethical concerns about
continued administration of the antibiotic control treat-
ment [52].
At present, the mechanism whereby FMT leads to
resolution of recurrent CDI is unclear. It is thought that
a sufficiently complex bolus of bacteria reverses the sup-
pressive effect of the pathogen on the endogenous
microbiome, allowing the re-establishment of colonization
resistance [73]. Restoration of the gut microbiome may in-
hibit sporulation, germination and/or vegetative growth of
Clostridium difficile. A few patients in this study had con-
tinuous diarrhea despite ongoing antimicrobial therapy. In
these cases, symptom relief could be observed as rapidly
as 48 hours post FMT, suggesting that even the small
number of bacteria present in the FMT dose can act, via
an unknown mechanism, to alleviate symptoms prior to
full reconstitution of a diverse endogenous microbiome.
Correction of metabolic dysfunction has been suggested
to play an important role [67]. A recent study associated
the presence of Clostridium scindens with resistance to
CDI and correlated the ability of this organism to gen-
erate secondary bile acids, inhibiting the growth of
Clostridum difficile [74].
In the present work, we integrated previous ap-
proaches to develop an innovative treatment protocol
for FMT. After homogenization with normal saline, low-
speed centrifugation was performed to remove particu-
late matter and then high speed centrifugation to
concentrate bacteria and reduce the final volume. Resus-
pension of the bacteria in 15% glycerol for cryopreserva-
tion has been previously validated to retain clinical
activity [25,75]. Encapsulation of stool material has been
presented in abstract form (Louie TJ et al., ‘Microbiome
profiles of recipients and donors post fecal transplantation
for multiple recurrent CDI infection,’ presented at 3rd
International Clostridium difficile Symposium, Slovenia)
and has been described in a publication released while this
manuscript was under review [76] (see discussion below).
With our protocol, the concentration of fecal-derived
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bacteria necessitated fewer capsules which may enhance
ease of administration. Cryopreservation rendered the
process safer and practical by obviating the need for
precise coordination of donor sample collection and by
facilitating extensive pathogen screening of each donor
sample. Our use of nested delayed-release capsules
within a smooth opaque gelatin capsule was aesthetic-
ally acceptable and easily managed by our patient popu-
lation while promoting effective delivery to the distal GI
tract.
We unexpectedly observed that the minimum effective
dose of bacteria for effective FMT was much lower than
the typical doses reported for the treatment of recurrent
CDI. Using the processing and encapsulation method-
ology applied here, rapid clinical efficacy was observed
in 70% of patients with a dose derived from less than 3 g
of input material, with an estimated 9.7×1010 viable bac-
teria per course. Typical FMT protocols described utilize
50–60 g for a single dose administered by colonoscopy,
with an entire fresh stool sample processed in order to
generate a single dose [28]. Importantly, however, one-
time FMT by colonoscopy has been reported to be more
effective than our minimum dose [40], whereas our
treatment protocol with 1–2 capsule doses was, cumula-
tively, as effective as colonoscopic FMT, suggesting that
our initial dose may be lower than optimal. We are
evaluating alternative dosing schedules and delivery
methods accordingly. The more efficient use of donor
material has major advantages. It is possible to generate
a large number of doses from a single instance of pro-
cessing, dramatically reducing costs associated with
pathogen screening. FMT material retained therapeutic
efficacy following 6 weeks of −20°C storage. In addition,
extensive pre-treatment measures such as bowel lavage
were not required for clinical efficacy. Taken together,
these advantages could allow this treatment modality to
be applied across many healthcare settings such as long-
term care facilities.
Three different donors were used to generate capsules
used in this case series. Material derived from all three
donors was clinically effective. No significant differences
in time to resolution of symptoms or efficacy among the
different donors were noted in this small sample. Future
studies with larger sample sizes would be required to
identify a dose–response relationship. For future investi-
gation, we plan to apply metagenomic analysis in an at-
tempt to better understand the recovery from marked
dysbiosis in recurrent CDI patients. An additional area
for future work includes more comprehensive screening
for potential asymptomatic low-level carriage of patho-
gens in donors. Clinically validated tests for enteric path-
ogens are generally designed to detect active infection.
We are currently developing approaches to detect a
wider range of bacterial and viral pathogens with high
sensitivity to improve the donor screening process. Patients
received a range of dosages. The high success rate,
small sample size and range of dosages precluded our
ability to determine a dose–response relationship.
Adjunctive measures were utilized to augment the ef-
fectiveness of FMT. Acute administration of a proton
pump inhibitor was used in an attempt to reduce the po-
tential loss of bacterial viability from stomach acid. The
acid-resistant nature of the capsules may render this
measure unnecessary; we are performing in vitro viabil-
ity assessment to clarify this. Kefir fermented milk prod-
uct has been described as beneficial in conjunction with
antibiotic therapy for CDI [77]. In that study a staggered
and tapered antibiotic withdrawal was combined with
regular ingestion of kefir liquid was effective in prevent-
ing diarrhea in 21/25 cases for 9 months following these
treatment. The use of short term kefir product may have
augmented efficacy in our study. However, a multicenter
randomized trial recently reported a lack of efficacy of a
widely used probiotic regimen for the prevention or
treatment of CDI [78]. Furthermore, a recent study of
encapsulated FMT for CDI demonstrated nearly identi-
cal clinical results without kefir, suggesting that in our
study, FMT was the primary factor in clinical response
[76]. Importantly, the recommended use of kefir requires
frequent and long-term consumption, unlike the one-
week intervention prescribed in our protocol.
The efficacy of FMT has implications for infection
control and public health. The patients in this series ex-
perienced prolonged diarrhea, in one case lasting over
one year. Clostridium difficile spores are hardy and can
remain viable in the environment for 5 months [79]. In
an animal model of recurrent CDI, antibiotic treatment
was shown to cause a ‘supershedder’ state whereby an
asymptomatic carrier sheds large numbers of Clostrid-
ium difficile spores; this supershedder state was sup-
pressed by FMT in the animal model [80]. Earlier
utilization of curative treatment for CDI is essential to
enhance the safety of the hospital environment and to
reduce the increasing frequency of community acquired
infection [81].
Reimbursement for FMT has been a major limiting
factor in its widespread use for recurrent CDI. This
treatment is recognized by the Center for Medicare &
Medicaid Services, which has assigned a specific billing
code; however, the reimbursement provided is relatively
low given the expense, labor, space and equipment re-
quired. The major factors in the expense associated with
FMT are clinician time and pathogen screening. Coord-
ination of donor screening, sample processing and FMT
is labor-intensive, especially using traditional FMT ap-
proaches. Donor recruitment and screening for patho-
gens (which can cost over $1000) are generally not
reimbursed. Our approach greatly improves the efficiency
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of this process, as many doses can be produced and
banked following one instance of screening. Another lim-
iting factor for efficient capsule production is the encapsu-
lation process itself, which at present (like traditional
FMT) requires significant hands-on clinician time imme-
diately prior to administration. We are developing methods
to improve capsule stability in order to further increase
the convenience and cost-effectiveness of this treatment
modality. Despite these issues, FMT for recurrent CDI
is highly cost-effective, as determined in a recently pub-
lished analysis [57]. In that study, even with a cost esti-
mate of over $3,000, colonoscopic FMT was found to
be the most cost effective treatment for first CDI recur-
rence when compared with metronidazole, vancomycin
or fidaxomicin. FMT utilizing the currently described
capsule method represents an efficient and non-invasive
strategy which preserves clinical, epidemiologic and eco-
nomic advantages of the colonoscopic approach.
Limitations of the present work include small sample
size and an incomplete understanding of dose–response
characteristics. However, our results are nearly identical
to a recent publication describing the use of frozen fecal
material administered in oral capsules [76]. That study
similarly followed 20 patients with at least 3 episodes of
mild to moderate CDI who had failed a 6- to 8-week
taper with vancomycin or had at least 2 episodes of se-
vere CDI requiring hospitalization. Patients were given
15 FMT capsules over 2 consecutive days and were sub-
sequently followed for symptom resolution and adverse
events for up to 6 months. Donors underwent similar
screening as the present work and capsules were created
and stored in a similar fashion. If patients did not
achieve improvement in their diarrhea after 72 hours,
they were retested and offered re-treatment if still posi-
tive. In that study, there was 70% resolution of diarrhea
after a single FMT treatment (14 out of 20 patients) and
an overall 90% rate of resolution (18 out of 20). The
highly similar response rates observed validate the re-
spective studies. Our study has certain additional limita-
tions including single arm design and absence of gut
microbiota evaluation. While we had follow-up on all
cases, we relied on patient and family report of clinical
status, reasoning that criteria for recurrence of CDI are
very clear to those so afflicted.
Conclusions
Our data suggest that FMT utilizing concentrated cryo-
preserved fecal-derived bacteria, administered via orally
ingested capsules, is an effective, safe and well-tolerated
therapy for recurrent CDI. The ease of administration
facilitates multiple courses of FMT if required. We are
able to demonstrate an overall success rate of 89%, with
68% experiencing cure from a single FMT. This efficacy
is comparable to that of more invasive FMT modalities.
Advantages of this approach include high efficacy, lack
of significant adverse effects, ease of administration, patient
comfort, non-invasiveness, ability to safely provide therapy
to those with extensive co-morbidities and advanced age,
and cost-effectiveness. This approach represents a powerful,
patient-friendly and cost-efficient option for the treatment
of recurrent and persistent CDI.
Additional file
Additional file 1: Table S2. CDI history, risk factors, treatments and
outcomes for patients receiving FMT. *This patient had continuous CDI
diarrhea for one year despite antimicrobial treatment. **Initial
improvement in symptoms was observed within 3 days; symptom
improvement continued over the course of 2 weeks.
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